Two inexpensive classes of drugs available in generic form each reduce the recurrence of breast cancer in post-menopausal women as well as death rates from the disease, a pair of studies reported Friday.
Taking the medications together may further boost anti-cancer benefits and help cancel out undesirable side-effects of one of the drugs, according to the research published in medical journal The Lancet.
The first "meta-study" pulling together data from nine trials covering 30,000 post-menopausal women found endocrine treatments based on a class of drugs called aromatase inhibitors yield higher survival rates after five years compared to standard endocrine therapy with tamoxifen.
The likelihood of cancer recurring was cut by about a third and the risk of dying by about 15 percent in the decade after treatment started. Compared to no treatment at all, the danger of dying from breast cancer fell by 40 percent, the study found.
Most women have already passed through menopause when breast cancer strikes. Even after surgery has removed all detectable traces, tiny amounts of the body's own hormones can cause cancer cells to grow.
Endocrine therapies are designed to impede these hormones from stimulating the disease, and so help protect against relapse.
"But aromatase inhibitor treatment is not free of side-effects and it's important to ensure that women" who suffer them are "supported", said the study's lead author, Mitch Dowsett of The Institute of Cancer Research in London.
The second meta-study, which scanned the results of 26 trials involving another 20,000 women, showed that another class of drugs called bisphosphonates -- usually taken to treat osteoporosis, a bone-weakening condition that becomes more common with age -- also significantly boosted survival when taken for at least two years.
When breast cancer spreads, bone is its favoured destination. Tumour cells released from the primary breast cancer can remain dormant in bones for years before moving to other parts of the body.
Bisphosphonates make the bones a less hospitable environment for the cancer cells and so reduce the risk of cancer recurring. The beneficial effect were found to be far more pronounced in post-menopausal women, regardless of the treatment duration, the size of the tumour or whether the cancer had spread to lymph nodes.
The therapy did not, however, reduce the risk of new cancers developing in the opposite breast.
"These simple, well-tolerated treatments should now be considered for routine use" in women with natural or medically induced menopause, lead author Robert Coleman from the University of Sheffield said in a statement.
Some two-thirds of all women with breast cancer are post-menopausal with hormone-sensitive tumours, so could potentially benefit from both drugs, the researchers conclude.
"The drugs are complementary," noted Oxford University's Richard Gray, lead statistician for the studies. "The main side effect of aromatase inhibitors is an increase in bone loss and fractures, while bisphosphonates reduce bone loss."
AFP RELAXNEWS
Fri Jul 24 2015
A study found that taking the medications together may further boost anti-cancer benefits.
AWANI Pagi: Pendayaupayaan Pembangunan Sosio Ekonomi Bagi Memacu Wilayah Persekutuan
Ikuti temu bual bersama Menteri di Jabatan Perdana Menteri (Wilayah Persekutuan), Dr Zaliha Mustafa di #AWANIPagi jam 7.30 pagi di saluran 501 Astro AWANI.
Pentagon, Jabatan Negara AS beri amaran jenayah perang Israel
Pegawai-pegawai tersebut telah memberi amaran peningkatan jumlah kematian di Gaza mungkin melanggar undang-undang antarabangsa.
200,000 pelarian tiba di Syria selepas serangan Israel ke atas Lubnan - UNHCR
Lebih 200,000 warga Syria dan Lubnan telah tiba di Syria dari Lubnan sejak serangan Israel bermula pada 23 Sept.
Belanjawan 2025: Kesalinghubungan internet di sekolah, kampus jadi keutamaan - Fahmi
Kementerian Komunikasi akan memberikan keutamaan dengan meneruskan usaha untuk meningkatkan dan memantapkan lagi prasarana kesalinghubungan melibatkan isu Internet, dalam Belanjawan 2025 yang akan dibentangkan pada 18 Okt ini.
Setahun solidariti, sokongan global untuk Palestin di tengah-tengah genosid berterusan Israel
Ribuan manusia di seluruh dunia turun ke jalanan untuk menyuarakan sokongan kepada Palestin dan menuntut keadilan.
Indonesia kecewakan China, raih kejuaraan badminton berpasukan campuran remaja dunia
Indonesia menewaskan China untuk muncul Juara Badminton Berpasukan Campuran Remaja Dunia dengan kemenangan 110-103 (mata terkumpul).
Bomba selamatkan tiga subkontrakor terkandas di kren pengangkat
Ketiga-tiga mangsa lelaki itu masing-masing berusia 24, 26 dan 32 tahun terkandas dengan anggaran ketinggian dua tingkat.
Hulu Perak daerah terbaharu dilanda banjir kilat
Banjir kilat berlaku disebabkan hujan lebat berterusan selama dua jam di sekitar Gerik.
Kejayaan pembangunan Sabah jadi kayu ukur pada PRN, PRU16 - Rafizi
Rafizi berkata kerjasama antara parti adalah perkara yang terus dibincangkan dalam kerangka semangat Kerajaan Perpaduan.
88 badan pensijilan halal luar negara dapat pengiktirafan JAKIM
Jabatan Kemajuan Islam Malaysia (JAKIM) telah memberikan pengiktirafan kepada 88 badan pensijilan halal luar negara setakat Mei tahun ini.